Skip to content

treatment of qooba (tinea cruris) with unani formulations

Efficacy of Majoon-e-Shahtara and Zimad in Tinea cruris â?? An Open Labelled Single Arm Interventional Clinical Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/023861
Enrollment
30
Registered
2020-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Majoon-e-Shahtara and Zimad, Unani formulations.: Majoon-e-Shahtara 7 g twice daily will be administered orally with water (after meal) and Zimad will be applied locally twice a day for

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and microscopically diagnosed patient of Tinea cruris Patient of either gender Age group 20-50 years Patient who have agreed to sign the informed consent form

Exclusion criteria

Exclusion criteria: Patient below 20 years and above 50 years of age Pregnant and lactating women Patient with severe systemic and metabolic disorders Diabetic, HIV/AIDS or other immunocompromised patients Patient with concomitant skin disease like eczema and psoriasis Patient who are taking conventional medicine for Tinea cruris will be enrolled for the trial after a washed out period of 15 days

Design outcomes

Primary

MeasureTime frame
Improvement in subjective parametersTimepoint: 28 days

Secondary

MeasureTime frame
Improvement in objective parametersTimepoint: 28 days

Countries

India

Contacts

Public ContactMOHAMMAD DANISH

National Institute Of Unani Medicine

dr.rumman190@gmail.com9450090387

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026